The announcement of the sale to an American investment fund in October had raised an outcry from political leaders and unions.
:quality(50)/2023/07/06/64a68815cd1a7_placeholder-36b69ec8.png)
Published
Updated
Reading time: 1min
:quality(50)/2025/04/30/sipa-01202283-000001-68126ca5401f1569135559.jpg)
Skull evil in sight for defenders of French industrial sovereignty. The Doliprane, the most prescribed drug in France, officially passed under the American pavilion, Wednesday April 30, with the finalization of the sale by Sanofi to the CD & R investment fund of the control of the company which produces the popular yellow box.
The closure of this operation, the announcement of which in October had aroused the shields of political leaders and unions, provides that Sanofi gives up 50% of its subsidiary Opella, while maintaining a participation of 48.2% in this company. “This change of shareholding does not change anything: Doliprane will remain in France for the French”assured the CEO of Opella, Julie Van Ongonvalle, during The General Assembly of Sanofi shareholders. With “The commitments made in social matters, jobs, investment, we have taken into account all the parties”For his part, said the Chairman of the Board of Directors of Sanofi, the former Banquier Frédéric Oudéa.
